Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors

« Previous Next »Seminars in Nuclear Medicine
Volume 36, Issue 2 , Pages 147-156, April 2006

Survival and Response After Peptide Receptor Radionuclide Therapy With [⁹⁰Y-DOTA⁰,Tyr³]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors

Roelf Valkema, MD, PhD
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
- Address reprint requests to Roelf Valkema, MD, Department of Nuclear Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.
Stanislas Pauwels, MD, PhD
- Department of Nuclear Medicine, Cliniques Universitaires St Luc, Catholic University of Louvain, Brussels, Belgium.
Larry K. Kvols, MD, PhD
- GI Tumor Program, H. Lee Moffitt Cancer Hospital, University of Florida, Tampa, FL.
Raffaella Barone, MD, PhD
- Department of Nuclear Medicine, Cliniques Universitaires St Luc, Catholic University of Louvain, Brussels, Belgium.
Francois Jamar, MD, PhD
- Department of Nuclear Medicine, Cliniques Universitaires St Luc, Catholic University of Louvain, Brussels, Belgium.
Willem H. Bakker, PhD
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
Dik J. Kwekkeboom, MD, PhD
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
Hakim Bouterfa, PhD
- Novartis Pharmaceutical Corporation, East Hanover, NJ.
Eric P. Krenning, MD, PhD
- Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
- Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands.